1 reports of this reaction
7.7% of all CHILDRENS ALLERGY RELIEF reports
#2 most reported adverse reaction
COVID 19 is the #2 most commonly reported adverse reaction for CHILDRENS ALLERGY RELIEF, manufactured by Allegiant Health. There are 1 FDA adverse event reports linking CHILDRENS ALLERGY RELIEF to COVID 19. This represents approximately 7.7% of all 13 adverse event reports for this drug.
Patients taking CHILDRENS ALLERGY RELIEF who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COVID 19 is moderately reported among CHILDRENS ALLERGY RELIEF users, representing a notable but not dominant share of adverse events.
In addition to covid 19, the following adverse reactions have been reported for CHILDRENS ALLERGY RELIEF:
The following drugs have also been linked to covid 19 in FDA adverse event reports:
COVID 19 has been reported as an adverse event in 1 FDA reports for CHILDRENS ALLERGY RELIEF. This does not prove causation, but indicates an association observed in post-market surveillance data.
COVID 19 accounts for approximately 7.7% of all adverse event reports for CHILDRENS ALLERGY RELIEF, making it one of the most commonly reported side effect.
If you experience covid 19 while taking CHILDRENS ALLERGY RELIEF, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.